TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Compumedics Limited ( (AU:CMP) ) is now available.
Compumedics Limited has secured early FDA approval for its Somfit D product and raised $2.15 million to accelerate its commercialization in the US home sleep testing market. The company is entering a significant commercial expansion phase, with strategic growth pillars including scaling Somfit in the US, expanding OrionMEG globally, and leveraging SaaS-driven margin expansion. The funds will be used to fast-track production and support the growing demand for Somfit D and OrionMEG, positioning Compumedics for a structural valuation re-rating against peers.
The most recent analyst rating on (AU:CMP) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Compumedics Limited stock, see the AU:CMP Stock Forecast page.
More about Compumedics Limited
Compumedics Limited is a leading global medical technology company specializing in sleep diagnostics, brain imaging, and neuro-monitoring. The company focuses on the US home sleep testing market and global neuroscience expansion, with products like Somfit® and OrionMEG®.
Average Trading Volume: 110,334
Technical Sentiment Signal: Buy
Current Market Cap: A$65.35M
Find detailed analytics on CMP stock on TipRanks’ Stock Analysis page.